<?xml version="1.0" encoding="UTF-8"?>
<p>In some cases, drug repositioning captures a high return on investment potential and covers monetary loss in the initial unpropitious outcome of drug development. For example, the once-controversial Thalidomide that was initially intended for sedative purposes is now mainly used for specific cancer treatments. Together with its derivative Lenalidomide, manufactured by Celgene, it successfully captured a more than $2.8 billion global revenue. This translated to a superior return on investment as compared to traditional novel chemical entity/new molecular moiety (NCE/NME) drugs [
 <xref rid="B73-viruses-12-01058" ref-type="bibr">73</xref>]. The NCE/NME drugs are the traditional drug discovery route where the discovered molecules would undergo clinical trials and await FDA approval for disease treatment.
</p>
